The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 42 new drugs across categories including antibiotics, anti-hypertensives, anti-diabetic medications, and anti-inflammatory formulations. The move aims to make essential medicines more affordable and ensure compliance with the Drugs Prices Control Order (DPCO), 2013. Manufacturers are required to issue price lists in Form-V and notify state drug controllers and retailers from the date of the NPPA notification.

Key Highlights:

Antibiotics

• Meropenem + Sulbactam injection(Zydus Healthcare) at ₹1,936.59 per vial for severe bacterial infections.

• Ceftriaxone + Tazobactam injection (FDC Ltd) at ₹190.26 per vial.

• Ofloxacin + Metronidazole oral suspension (Alkem/Abbott) at ₹1.04 per 1 ml.

• Cefixime + Ofloxacin oral suspension (FDC Ltd) at ₹2 per ml.

• Clarithromycin 1000 mg extended-release tablets at ₹71.71 (Healthcare Pvt Ltd).

• Mycophenolate Mofetil 750 mg tablets at ₹131.58 (Toca Laboratories).

Anti-diabetics

• Tapagliflozin, Glimepiride & Metformin HCl extended-release (Dr Reddy’s Laboratories).

• Empagliflozin, Sitagliptin & Metformin HCl extended-release (Cadila, Natco, MSN, and others).

• Prices fixed across multiple brands to ensure affordability and compliance with NLEM provisions.

Anti-hypertensives & Cardiac Drugs

• Telmisartan + Amlodipine combinations (Primus Remedies, Workcail Solutions).

• Amlodipine + Bisoprolol fumarate (Torrent Pharmaceuticals).

• Rosuvastatin + Aspirin + Clopidogrel capsules  (K. Specialties).

Regulatory compliance

• Manufacturers must follow NPPA-mandated retail prices and issue Form-V price lists.

• Copies must be submitted to State Drug Controllers and supplied to retailers via IP DMS.

• This ensures uniform pricing across markets and prevents overcharging.

Previous NPPA actions

• The last NPPA meeting had fixed prices for 38 formulations, including various anti-diabetes combinations.

• New pricing covers drugs launched with modified strengths or combinations of medicines already listed in the National List of Essential Medicines (NLEM).

  
  

The NPPA’s latest price fixation brings 42 critical formulations under regulated retail pricing, improving affordability for patients and ensuring compliance across the pharmaceutical supply chain. Pharmacists should update their Form-V price lists immediately and ensure adherence to the notified rates to avoid regulatory issues.